MyKronoz Introduces ZePods Fashionable and Colorful True Wireless Earbuds, Together with a New Line of Affordable Smartwatches
Swiss wearable brand MyKronoz today announced ZePods, its first collection of true wireless earphones, unveiled at Mobile World Congress Barcelona 2019. Offering an impressive sound quality, up to 15 hours of playtime, stylish design with 6 vibrant colors and matching USB-C charging case, intuitive touch control to manage music, calls and voice commands thanks to its Bluetooth 5.0 technology - MyKronoz’s first true wireless earbuds will come in two versions with distinctive design and features:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190226005577/en/
ZePods - Wireless TWS earbuds (Photo: MyKronoz)
- ZePods, with a USB-C charging case boasting the familiar look of a sleek lighter. Available in April 2019 for a MSRP of 79,90€/$ only.
- ZePods+, with a Qi-certified wireless charging case whose shape has been greatly inspired by Swiss traditional pocket-watch. Available H2 2019 for a MSRP of 99,90€/$.
"Building on our Swiss DNA for design and our strong background in wearable technology, we believe that MyKronoz has a tremendous opportunity to seize in the flourishing market of wireless earbuds. The launch of ZePods appears as a natural and strategic evolution for our company to leverage expertise in developing affordable consumer-driven products and diversify to offer a full ecosystem." said Boris Brault, MyKronoz Founder and CEO.
In addition to ZePods, MyKronoz goes back to basics of affordable fashion wearables with a complete new line starting at 29.90 €/$, featuring activity tracker, smartwatches, sport smartwatches and hybrids to cater a large and diversified audience. Among the new collection, 4 products highlights:
- ZeTrack - a slim and full-featured HR activity tracker with color touchscreen. MSRP: 29.90€/$ - Launch date: end of March 2019.
- ZeNeo - a real powerful smartwatch with mic & speaker that looks like a sleek activity tracker. MSRP: 59.90€/$ - Launch date: end of April 2019.
- ZeRound3 Lite - the go-to smartwatch designed for your active lifestyle. MSRP: 79.90€/$ - Launch date: end of April 2019.
- ZeRound3 - the genuinely stylish connected smartwatch with AMOLED display. MSRP: 99.90€/$ - Launch date: end of March 2019.
The rest of the range includes ZeSport2, a multi-sport GPS smartwatch, already available at a MSRP of 149.90€/$. MyKronoz will continue to innovate in H2 2019 with ZePop - the hybrid smartwatch that blends fashion and tech. MSRP: 129,90€/$ as well as ZeTime2 - a stainless steel hybrid smartwatch with microphone, AMOLED display and real mechanical hands. MSRP: 199,90€/$.
ZePods, as well as the MyKronoz full new wearable collection will be on display and available for demos on the MWC 2019 show foor at the MyKronoz booth in the Congress Square (Booth #CS118) February 25-28th, 2019.
ABOUT MYKRONOZ:
MyKronoz is part of BOW Group, a global player in lifestyle consumer products, operating worldwide in the design and wearables markets with its 2 brands: MyKronoz and LEXON.
Since July 2015, BOW has opened up its capital to Next Stage AM, then, in 2017 to PM Equity Partner - the corporate venture fund of Philip Morris International. MyKronoz ZeTime has convinced over 40,000 backers in more than 100 countries and became the world's highest funded hybrid smartwatch with more than $8 million raised, as well as the largest crowdfunding campaign ever from a European company and the most backed product of 2017 on Kickstarter.
BOW Group has now more than 100 talents spread across four office locations: Paris, Geneva, Miami and Shenzhen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190226005577/en/
Contact information
International media:
Annabel
Corlay
press@mykronoz.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
